Anumber of clinical trials have demonstrated
|
|
- Cecil Cameron
- 5 years ago
- Views:
Transcription
1 IMPROVING THE UTILITY OF PHENOTYPE RESISTANCE ASSAYS: NEW CUT-POINTS AND INTERPRETATION * Richard Haubrich, MD ABSTRACT The interpretation of a phenotype assay is determined by the cut-point, which defines whether the patient s virus is susceptible or has reduced susceptibility to the drug being studied. More recently, biologically defined cut-points, derived from the range of drug susceptibilities in therapy-naive isolates, have helped to define the fold change in inhibitory concentration of 50% (IC 50 ) that can be expected to reduce drug susceptibility. Virtual phenotype (VIRCO) assays have also been used. The best way to identify cut-points is to relate the susceptibility of a drug to the virological response to a regimen that contains that drug. Cut-points defined by this method are referred to as clinical cut-points. The CCTG 575 investigators examined phenotypic cut-points to determine the correlation of phenotype with drug susceptibility and virologic response in a group of patients who failed on at least 1 previous regimen. A phenotype, determined at baseline, was used to evaluate the number of susceptible drugs by class (nucleoside reverse transcriptase inhibitors [NRTIs], nonnucleoside reverse transcriptase inhibitors [NNRTIs], and protease inhibitors [PIs]) in the regimen. Investigators concluded that phenotypic susceptibility to PIs and NNRTIs were strong predictors of response when using a cut-point of 2.5, even after correction for baseline CD4 and HIV RNA. (Advanced Studies in Medicine 2001;1(12): ) *This article is based in part on a presentation given by Dr Haubrich at the 1st International AIDS Society Conference on HIV Pathogenesis and Treatment. Correspondence to Richard Haubrich, MD, Associate Professor of Medicine, Division of Infectious Diseases, University of California San Diego, 150 West Washington Street, Suite 100, San Diego, California Anumber of clinical trials have demonstrated that resistance testing, used to select drugs for the next regimen when a patient is failing his or her current therapy, can result in improved clinical outcome, which has been defined as short-term (12- to 24-week) suppression of HIV RNA levels. However, not all of the studies have revealed a positive impact of resistance testing, including 2 recent studies that failed to show better virologic suppression in the resistance testing arms compared to patients treated without resistance testing. The variable success of prospective trials of phenotype-resistance guided therapy initially considered to yield results that were easier to interpret may have been due to difficulty of interpreting HIV-resistance tests. This difficulty has been attributed to the lack of clinical guidelines for interpretation of the data from these assays. The interpretation of a phenotype assay is determined by the cut-point, which defines whether the patient s virus is susceptible or has reduced susceptibility to the drug being studied. It is presumed that use of more susceptible drugs in a treatment regimen will be more likely to result in virologic suppression than use of less susceptible drugs. Phenotype assays initially used cut-points based on assay reproducibility, the retesting of a sample multiple times to determine the range of assay variability. For the ViroLogic phenotype assay, if the fold change in inhibitory concentration of 50% (IC 50 ) of the patient s virus varied more than 2.5-fold from control, it could be assumed that the virus was less susceptible to the drug than a wild-type (nonresistant) virus. More recently, biologically defined cut-points, derived from the range of drug susceptibilities in therapy-naïve isolates, have helped to define the fold change in IC 50 that can be expected to reduce drug susceptibili- 486 Vol. 1, No. 12 December 2001
2 ty. To determine the biological cut-point, a large number of phenotype values are evaluated from treatment-naïve patients with no prior therapy. The range of susceptibilities for these patients is then examined, and a metric, such as the mean +2 standard deviations, is used to define the upper range of susceptibility for the assay. Patient samples with a fold change in IC 50 beyond this upper range would be defined as having reduced susceptibility. Although phenotype cut-points for RTV boosted PI are not yet available for all the drugs, there are a number of ongoing studies designed to help improve this knowledge base. In one study of 240 treatment-naïve patients, the 95% confidence interval (the mean +2 standard deviations) for a cut-point was examined for the ViroLogic PhenoSense assay. The upper limit of the confidence interval for the nucleoside reverse transcriptase inhibitor (NRTI) drugs is shown in Table 1. In naïve patients, there is little variation in susceptibility for stavudine (d4t) and didanosine (ddi); for d4t and ddi, most of the samples were <1.5, while for zidovudine (AZT), normal values can range as high as 1.9. Similar analyses have been conducted using VIRCO assays to determine the biologic cut-point for that assay. In Table 2, the old and new cut-points for the VIRCO assay are listed for selected drugs. The percentages of samples with resistance, defined by the old and new cut-points from 5000 samples in the VIRCO database, are presented. Investigators defined the new cut-points for the assay by testing a large number of clinical samples (not the samples included in Table 2) from treatment-naïve patients. These cut-points differ from those of the ViroLogic assay due to intrinsic differences in the way the assays are conducted. In the case of VIRCO, the original cut-point for all of the nucleosides based on assay reproducibility was 4.0. Table 2 illustrates the impact of the new biologic cutpoints. For example, the previous cut-point for d4t was 4.0. Using this value, 7% of the 5000-patient sample would have been classified as resistant, while with the new cut-point of 3.0, 12% of the patients would be considered resistant. As can be seen by comparing Tables 1 and 2, cut-points are different for the 2 different assays. Clinicians must be aware of which assay has been performed and recognize the different cut-points for each assay when selecting drugs for a regimen. Unfortunately, cut-points derived from biological variation are not optimal. The best way to identify cutpoints is to relate the susceptibility of a drug to the virological response to a regimen that contains that drug. Cut-points defined by this method are referred to as clinical cut-points. One of the most important issues in resistance testing is therefore the identification of phenotypic breakpoints for individual drugs that are based on therapeutic response to a regimen. Table 1. Biologic Cut-offs for PhenoSense Assay Vary by Drug Drug 95th Percentile susceptibility fold change AZT 1.9 3TC 1.5 d4t 1.5 ddl 1.5 ddc 1.6 ABC 1.7 Variability of drug susceptibility in virus from treatment-naïve patients. AZT = zidovudine; 3TC = lamivudine; d4t = stavudine; ddi = didanosine; ddc = zalcitabine; ABC = abacavir. Table 2. Effect of New Cut-offs: 5000 VIRCO Clinical Samples Old % New % Drug Cut-point Resist Cut-Point Resist AZT d4t ABC EFV APV AZT = zidovudine; d4t = stavudine; ABC = abacavir; EFV = efavirenz; APV = amprenavir. Advanced Studies in Medicine 487
3 Few studies that differentiate clinical cut-points have been conducted. One recent meta-analysis of 4 early trials of therapeutic intensification with abacavir (ABC) that evaluated the addition of ABC to a failing regimen identified 2 clinically relevant breakpoints using the PhenoSense assay. Since the only drug that was changed at baseline was ABC, the change in HIV RNA from baseline would be due to the effects of ABC and this response to ABC is related to the phenotypic susceptibility to ABC at baseline. In this analysis, a 4.5-fold reduction in susceptibility to ABC marked the point at which the likelihood of a plasma HIV-1 RNA decrease to <400 copies/ml was significantly reduced. Patients with a 6.5-fold reduction were not likely to have significant viral load reductions. Phenotypic analysis of samples from older, monotherapy trials can also help define assay breakpoints. One study evaluated patients treated with AZT monotherapy who then received d4t. Phenotypic evaluation of AZTtreated patients showed very small differences in d4t susceptibility. Virologic response (>-0.3 log 10 reduction in HIV RNA) was seen for patients with median d4t susceptibility of 1.0. Non-responders had an average fold change of 1.6 to d4t. Another analytical method to define phenotypic cutpoints is to relate virologic response to baseline phenotype in patients receiving different baseline regimens. This presents a greater analytic challenge because of the impact of a variety of different regimens. The CCTG 575 investigators have examined phenotypic cut-points to determine the correlation of phenotype with drug susceptibility and virologic response in a group of patients who failed on at least 1 previous regimen (Table 4). Virologic success was defined as having HIV RNA <400 copies/ml at 6 or 12 months. Patients had an average of 36 months of prior therapy and switched to different regimens at baseline. A phenotype, determined at baseline, was used to evaluate the number of susceptible drugs by class (NRTIs, nonnucleoside reverse transcriptase inhibitors [NNRTIs], and protease inhibitors [PIs]) in the regimen. Susceptibility in the initial models was defined using a 2.5-fold cut-point. In the multivariate models, logistic regression was used, controlling for baseline CD4 and HIV RNA. Changes in odds ratios or P-value were evaluated for differences in NRTI cut-points. The Figure shows the distribution of susceptibility to ddi in the CCTG 575 sample population of more than 200 experienced patients with an average of 36 Table 3. Predictors of Virological Response to Stavudine (d4t) After Zidovudine (AZT) Monotherapy [ACTG 302] " Efficacy of d4t monotherapy in monotherapy-experienced patients (genotyped, n=31 & phenotyped, n=24) " Small decreases in d4t phenotypic susceptibility were associated with nonresponse " The clinically relevant phenotypic cut-off for d4t in this study was <1.5 fold " No patient with >1 thymidine analogue mutation (TAM) had a significant reduction in viral load (> -0.3 Log 10 ) with d4t therapy Shulman et al. Genotypic Predictors of Virologic Response to Stavudine after Zidovudine monotherapy (ACTG 302). Presented at: 8th Conference on Retroviruses and Opportunistic Infections; February 4-8, 2001; Chicago, IL. Abstract 437. d4t = stavudine; AZT = zidovudine. Table 4. CCTG 575 Statistical Methods " Virologic outcome: % HIV RNA <400 copies/ml at months 6 and 12 " Baseline regimen evaluated for the number of susceptible drugs; all drugs and by ARV class (NRTI, PI, and NNRTI) " Definitions of susceptibility to a drug: " FC <2.5 for all drugs " FC <2.0 or 1.5 for ddl and d4t " substitution of AZT FC for d4t; ABC FC for ddl ARV = antiretroviral; NRTI = nucleoside reverse transcriptase inhibitor; PI = protease inhibitor; NNRTI = nonnucleoside reverse transcriptase inhibitor; ddi = didanosine; d4t = stavudine; AZT = zidovudine; FC = fold change; ABC = abacavir. 488 Vol. 1, No. 12 December 2001
4 months of nucleosides, 45% of whom had prior ddi. Only 13 patients had any level of reduced susceptibility when the cut-point for the drug was at 2.5. A similar result was seen with d4t, demonstrating that a cut-point of 2.5 for ddi or d4t may not be a sensitive indicator for determining which patients are likely to respond to either of those drugs. Virologic response, based on the number of susceptible drugs in the baseline regimen, demonstrated that for patients whose viral isolates had 3 susceptible drugs in their baseline regimen, 53% responded versus 32% of patients who had <3 susceptible drugs. If d4t and ddi are excluded from the analysis and not counted among susceptible drugs, almost the same result occurs, suggesting that d4t and ddi do not add to the predictive value of the baseline phenotype relating to virologic success. A multivariate model was then constructed to define the relative contribution of the various drug classes in predicting response. If the baseline regimen contained a PI to which the patient s virus was susceptible, the patient was twice as likely to reach undetectable viral load levels. A susceptible NNRTI in the baseline regimen improved the chances of having HIV RNA < 400 copies/ml at month 6 by 3-fold. Susceptible NRTIs did not appear to add to the predictive value of the phenotype. In subsequent multivariate models, the cutpoint of 1.5 was used for d4t and ddi while the cut-point for the other drugs was maintained at 2.5. In these models, susceptibility to both PIs and NNRTIs remained important predictors. The predictive value of susceptibility to NRTIs did improve with the new cut-points, but not to statistically significant levels. CCTG 575 investigators concluded that phenotypic susceptibilities to PIs and NNRTIs were strong predictors of response when using a cut-point of 2.5, even after correction for baseline CD4 and HIV RNA. By lowering the phenotypic cut-points to 1.5 for d4t and ddi, the predictive value of using NRTIs in multivariate models was improved. One question remains: why did the NRTIs fail to be predictive in these models? One explanation is that a cut-point of 2.5 for d4t and ddi is not the optimal predictor of response. Also, many of the patients in the study had received prior HIV therapy with dual NRTIs for approximately 2 years before their first PI regimen was initiated. This previous drug experience might have diminished the effectiveness of the NRTIs in the subsequent baseline regimen. Given the low potency of these agents in the CCTG 575 population, the statistical power to discern the impact of an NRTI in a regimen with more potent agents (NNRTIs and PIs) was reduced. It is hoped that by using new cut-points, the usefulness of phenotype testing will be improved. DISCUSSION PERIOD Dr Miller*: Is it possible that resistance to NRTIs or the inability to predict susceptibility might be related to assay technology, which requires further improvement? Or is cross-resistance among the classes so much higher than we expected? Figure. Low Prevalence of ddl Resistance in Experienced Patients *Veronica Miller, MD, JW Goethe Universitaet, Klinkum der JW Goethe Universitaet, Theordor Stern Kai 7, Frankfurt, Germany. ddi = didanosine; FC = fold change. Advanced Studies in Medicine 489
5 Dr Haubrich: I think it is probably a combination of both. Both genotype and phenotype assays have difficulty defining resistance to d4t and ddi. Using cutpoints of 2.5, very few individuals had d4t or ddi resistance, even with extensive prior treatment with the nucleosides. Cross-resistance among the NRTIs is now better defined. There is increasing evidence that many of the so-called AZT mutations probably affect d4t as well. Since the range of phenotypic susceptibilities for d4t and ddi is narrow, an assay with the least amount of intra-assay variation should be used in order to discern subtle differences between viral isolates that are susceptible from those that are not. Dr Miller: How would you use these assays in the care of your patients? Dr Haubrich: I think resistance testing is indicated for all patients failing any highly active antiretroviral therapy regimen. The biologic and clinical cutpoints of each drug will continue to be refined. This in turn will improve our use of assays. For example, both VIRCO and ViroLogic have defined new cutpoints for the nucleosides. As I mentioned for d4t and ddi, the virologic assay uses 1.7. With abacavir, we have a clinical cut-point of 4.5. Consequently, using these new cut-points will improve our ability to select a new regimen. The wide range of cross-resistance that develops limits treatment options. If a patient shows cross-resistance to all drugs which is becoming more and more common for patients who have cycled through 3, 4, and 5 regimens accurately defining this resistance does not improve treatment options. However, it may help increase the likelihood of achieving some reduction in the viral load and maintain T cell counts even in the absence of complete virologic suppression. Suggested Reading 1. Costagliola D, Descamps D, Calvez V, et al. Presence of thymidine-associated mutations and response to d4t, abacavir and ddi in the control arm of the Narval ANRS 088 trial. Presented at: 8th Conference on Retroviruses and Opportunistic Infections; February 4-8, 2001; Chicago, IL. Abstract Shulman N, Shafer R, Winters M, et al. Genotypic predictors of virologic response to stavudine after zidovudine monotherapy (ACTG 302). Presented at: 8th Conference on Retroviruses and Opportunistic Infections; February 4-8, 2001; Chicago, IL. Abstract Lanier ER, Hellmann N, Scott J, et al. Determination of a clinically relevant phenotypic resistance cutoff for abacavir using the PhenoSense assay. Presented at: 8th Conference on Retroviruses and Opportunistic Infections; February 4-8, 2001; Chicago, IL. Abstract Haubrich R, Keiser P, Vitt M, et al. CCTG 575: a randomized, prospective study of phenotype testing versus standard of care for patients failing antiretroviral therapy. Antiretroviral Ther. 2001;6:63. Abstract Vol. 1, No. 12 December 2001
Perspective Resistance and Replication Capacity Assays: Clinical Utility and Interpretation
Perspective Resistance and Replication Capacity Assays: Clinical Utility and Interpretation Resistance testing has emerged as an important tool for antiretroviral management. Research continues to refine
More informationManagement of NRTI Resistance
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Management of NRTI Resistance David Spach, MD Principal Investigator, NW AETC Professor of Medicine, Division of Infectious Diseases University of Washington
More informationBecause accurate and reproducible phenotypic susceptibility
BRIEF REPORT: CLINICAL SCIENCE Comparison of the Precision and Sensitivity of the Antivirogram and PhenoSense HIV Drug Susceptibility Assays Jie Zhang, MS,* Soo-Yon Rhee, MS,* Jonathan Taylor, PhD, and
More information2 nd Line Treatment and Resistance. Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012
2 nd Line Treatment and Resistance Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012 Overview Basics of Resistance Treatment failure Strategies to manage treatment failure Mutation Definition: A change
More informationSomnuek Sungkanuparph, M.D.
HIV Drug Resistance Somnuek Sungkanuparph, M.D. Associate Professor Division of Infectious Diseases Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University Adjunct Professor
More information1592U89 (Abacavir) Resistance and Phenotypic Resistance Testing
1592U89 (Abacavir) Resistance and Phenotypic Resistance Testing Reported by Jules Levin, Executive Director of NATAP (3 March 1998) The following report contains a comprehensive update of the latest information
More informationManagement of patients with antiretroviral treatment failure: guidelines comparison
The editorial staff Management of patients with antiretroviral treatment failure: guidelines comparison A change of therapy should be considered for patients if they experience sustained rebound in viral
More informationTOXICITY, TOLERABILITY, AND ADHERENCE TO THERAPY
SAFETY AND TOLERABILITY OF CURRENTLY AVAILABLE ANTIRETROVIRAL AGENTS * Esteban Martinez, MD, PhD ABSTRACT Safety and tolerability are important factors to consider when instituting or modifying therapy
More informationNOTICE TO PHYSICIANS. Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases, National Institutes of Health
NOTICE TO PHYSICIANS DATE: March 10, 2003 TO: FROM: SUBJECT: HIV/AIDS Health Care Providers Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases, National Institutes of Health
More informationIntroduction to HIV Drug Resistance. Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School
Introduction to HIV Drug Resistance Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School Objectives 1. Describe the epidemiology of HIV drug resistance in sub-saharan Africa. 2.
More informationResistance Workshop. 3rd European HIV Drug
3rd European HIV Drug Resistance Workshop March 30-April 1 st, 2005 Christine Hughes, PharmD Clinical Associate Professor Faculty of Pharmacy & Pharmaceutical Sciences University of Alberta Tenofovir resistance
More informationPrinciples of Antiretroviral Therapy
Principles of Antiretroviral Therapy Ten Principles of Antiretroviral Therapy Skills Building Workshop: Clinical Management of HIV Infection and Antiretroviral Therapy, 11 th ICAAP, November 21st, 2011,
More informationSecond-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Second-Line Therapy David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases University of Washington Presentation
More informationNNRTI Resistance NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER NNRTI Resistance David H. Spach, MD Principal Investigator, NW AETC Professor of Medicine, Division of Infectious Diseases University of Washington Last Updated:
More informationMEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 03/07/18 SECTION: DRUGS LAST REVIEW DATE: 02/19/19 LAST CRITERIA REVISION DATE: ARCHIVE DATE:
FUZEON (enfuvirtide) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationSubtle Decreases in Stavudine Phenotypic Susceptibility Predict Poor Virologic Response to Stavudine Monotherapy in Zidovudine-Experienced Patients
JAIDS Journal of Acquired Immune Deficiency Syndromes 31:121 127 2002 Lippincott Williams & Wilkins, Inc., Philadelphia Rapid Communications Subtle Decreases in Stavudine Phenotypic Susceptibility Predict
More informationHIV Drug Resistance: An Overview
Human Journals Review Article October 2015 Vol.:1, Issue:1 All rights are reserved by Suraj Narayan Mali et al. HIV Drug Resistance: An Overview Keywords: HIV drug resistance mechanism, Antiretroviral
More informationPAEDIATRIC HIV INFECTION. Dr Ashendri Pillay Paediatric Infectious Diseases Specialist
PAEDIATRIC HIV INFECTION Dr Ashendri Pillay Paediatric Infectious Diseases Specialist Paediatric HIV Infection Epidemiology Immuno-pathogenesis Antiretroviral therapy Transmission Diagnostics Clinical
More informationCase Study. Dr Sarah Sasson Immunopathology Registrar. HIV, Immunology and Infectious Diseases Department and SydPath, St Vincent's Hospital.
Case Study Dr Sarah Sasson Immunopathology Registrar HIV, Immunology and Infectious Diseases Department and SydPath, St Vincent's Hospital Case 1: Case 1: 45F in Cameroon Cameroon HIV+ Presents with cutaneous
More informationIntegrase Strand Transfer Inhibitors on the Horizon
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Integrase Strand Transfer Inhibitors on the Horizon David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, University of Washington Presentation
More informationDNA Genotyping in HIV Infection
Frontier AIDS Education and Training Center DNA Genotyping in HIV Infection Steven C. Johnson M.D. Director, University of Colorado HIV/AIDS Clinical Program; Professor of Medicine, Division of Infectious
More informationHIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University
HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start
More informationWhat's new in the WHO ART guidelines How did markets react?
WHO 2013 ARV Guidelines What's new in the WHO ART guidelines How did markets react? Dr. J. Perriëns Coordinator, HIV Technology and Commodities HIV department, WHO, Geneva When to start in adults Starting
More informationClinical skills building - HIV drug resistance
Clinical skills building - HIV drug resistance Richard Lessells Clinical case 44-year old HIV-positive male HIV diagnosis 2010 Pre-treatment CD4+ count not known Initiated first-line ART (TDF/FTC/EFV)
More informationHIV Drug Resistance. Together, we can change the course of the HIV epidemic one woman at a time.
HIV Drug Resistance Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject What Is Resistance? HIV drugs are designed to keep the amount of HIV virus
More informationAntiviral Therapy 2013; 18: (doi: /IMP2329)
Antiviral Therapy 2013; 18:213 219 (doi: 10.3851/IMP2329) Original article Second-line protease inhibitor-based antiretroviral therapy after non-nucleoside reverse transcriptase inhibitor failure: the
More informationABC/3TC/ZDV ABC PBO/3TC/ZDV
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationBroad Nucleoside Reverse-Transcriptase Inhibitor Cross-Resistance in Human Immunodeficiency Virus Type 1 Clinical Isolates
MAJOR ARTICLE Broad Nucleoside Reverse-Transcriptase Inhibitor Cross-Resistance in Human Immunodeficiency Virus Type 1 Clinical Isolates Jeannette M. Whitcomb, Neil T. Parkin, Colombe Chappey, Nicholas
More informationDifferences in Calculated Glomerular Filtration Rates (GFR) in Efavirenz (EFV) or Tenofovir (TDF)-treated Adults in ESS40006
13th Conference on Retroviruses and Opportunistic Infections Denver, CO, USA. February 5-9, 2006 Poster Number 777 Differences in Calculated Glomerular Filtration Rates (GFR) in Efavirenz (EFV) or Tenofovir
More informationVirological suppression and PIs. Diego Ripamonti Malattie Infettive - Bergamo
Virological suppression and PIs Diego Ripamonti Malattie Infettive - Bergamo Ritonavir-boosted PIs Boosted PIs: 3 drugs in one The intrinsic antiretroviral activity Viral suppression and high baseline
More informationGenotypic Resistance in HIV-infected Patients Failing a d4t/3tc/nvp Regimen
Original Article Genotypic Resistance in HIV-infected Patients Failing a d4t/3tc/nvp Regimen Somnuek Sungkanuparph, M.D.* Weerawat Manosuthi, M.D.* Sasisopin Kiertiburanakul, M.D.* Wasun chantratita, Ph.D.**
More informationThe Use of Resistance Testing in HIV
The Use of Resistance Testing in HIV Dushyantha Jayaweera, M.D., M.R.C.O.G., F.A.C.P. Professor in Clinical Medicine Division of Infectious Diseases University of Miami Miller School of Medicine Viral
More informationAntiretroviral treatment outcomes after the introduction of tenofovir in the public-sector in South Africa
Antiretroviral treatment outcomes after the introduction of tenofovir in the public-sector in South Africa Alana T Brennan, Kate Shearer, Mhairi Maskew, Prudence Ive, Ian Sanne, Matthew P Fox Health Economics
More information0.14 ( 0.053%) UNAIDS 10% (94) ( ) (73-94/6 ) 8,920
0.14 UNAIDS 0.053% 2 250 60 10% 94 73 20 73-94/6 8,920 12 43 Public Health Service Task Force Recommendations 5-10% for Use of Antiretroviral Drugs in 10-20% Pregnant HIV-1-Infected Women for Maternal
More informationAntiviral Activity of Tenofovir Alafenamide against HIV-1 with Thymidine Analog Mutation(s) and M184V
Antiviral Activity of Tenofovir Alafenamide against HIV-1 with Thymidine Analog Mutation(s) and M184V Christian Callebaut, PhD Gilead Sciences, Foster City, CA, USA HIV DART AND EMERGING VIRUSES 12/08/2016
More informationHigher Risk of Hyperglycemia in HIV-Infected Patients Treated with Didanosine Plus Tenofovir
6131_06_p333-337 4/5/06 10:28 AM Page 333 AIDS RESEARCH AND HUMAN RETROVIRUSES Volume 22, Number 4, 2006, pp. 333 337 Mary Ann Liebert, Inc. Higher Risk of Hyperglycemia in HIV-Infected Patients Treated
More informationHistory (August 2010) Therapy for Experienced Patients. History (September 2010) History (November 2010) 12/2/11
(August 2010) Therapy for Experienced Patients Hiroyu Hatano, MD, MHS Assistant Professor of Medicine University of California San Francisco Medical Management of AIDS December 2011 42M HIV (CD4=450, VL=6250,
More informationPediatric Antiretroviral Resistance Challenges
Pediatric Antiretroviral Resistance Challenges Thanyawee Puthanakit, MD The HIVNAT, Thai Red Cross AIDS research Center The Research Institute for Health Science, Chiang Mai University Outline The burden
More informationVirologic and CD4 Cell Response to Zidovudine or Zidovudine and Lamivudine Following Didanosine Treatment of Human Immunodeficiency Virus Infection
AIDS RESEARCH AND HUMAN RETROVIRUSES Volume 17, Number 3, 2001, pp. 203 210 Mary Ann Liebert, Inc. Virologic and CD4 Cell Response to Zidovudine or Zidovudine and Lamivudine Following Didanosine Treatment
More informationPhenotypic resistance testing of HIV-1 strains can provide
CLINICAL SCIENCE Determination of Clinically Relevant Cutoffs for HIV-1 Phenotypic Resistance Estimates Through a Combined Analysis of Clinical Trial and Cohort Data Bart Winters, MSc,* Julio Montaner,
More informationSupplemental Digital Content 1. Combination antiretroviral therapy regimens utilized in each study
Supplemental Digital Content 1. Combination antiretroviral therapy regimens utilized in each study Study Almeida 2011 Auld 2011 Bassett 2012 Bastard 2012 Boulle 2008 (a) Boulle 2008 (b) Boulle 2010 Breen
More informationContinuing Education for Pharmacy Technicians
Continuing Education for Pharmacy Technicians HIV/AIDS TREATMENT Michael Denaburg, Pharm.D. Birmingham, AL Objectives: 1. Identify drugs and drug classes currently used in the management of HIV infected
More informationTreatment strategies for the developing world
David A Cooper National Centre in HIV Epidemiology and Clinical Research The University of New South Wales Sydney, Australia First line standard of care First line in the developing world First line failure
More informationTreatment of HIV-1 in Adults and Adolescents: Part 2
Treatment of HIV-1 in Adults and Adolescents: Part 2 Heather E. Vezina, Pharm.D. University of Minnesota Laboratory Medicine & Pathology Experimental & Clinical Pharmacology wynnx004@umn.edu Management
More informationWhole genome deep sequencing of HIV reveals extensive multi-class drug resistance in Nigerian patients failing first-line antiretroviral therapy
Whole genome deep sequencing of HIV reveals extensive multi-class drug resistance in Nigerian patients failing first-line antiretroviral therapy K El Bouzidi 1,, RP Datir 1, V Kwaghe 3, S Roy 1, D Frampton
More informationLiver Toxicity in Epidemiological Cohorts
SUPPLEMENT ARTICLE Liver Toxicity in Epidemiological Cohorts Stephen Becker Pacific Horizon Medical Group, San Francisco, California Hepatotoxicity has been demonstrated to be associated with antiretroviral
More informationComprehensive Guideline Summary
Comprehensive Guideline Summary Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents AETC NRC Slide Set Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and
More informationDifferentiating emtricitabine (FTC) from lamivudine (3TC): what a fine-tuning of antiretroviral therapy might entail
HAART, HIV correlated pathologies and other infections Renato Maserati Differentiating emtricitabine (FTC) from lamivudine (3TC): what a fine-tuning of antiretroviral therapy might entail Corresponding
More informationScottish Medicines Consortium
Scottish Medicines Consortium raltegravir, 400mg film-coated tablet (Isentress) No. (461/08) Merck, Sharp and Dohme Limited 04 April 2008 The Scottish Medicines Consortium has completed its assessment
More informationReal Life Experience of Dolutegravir and Lamivudine Dual Therapy As a Switching Regimen in HIVTR Cohort
Real Life Experience of Dolutegravir and Lamivudine Dual Therapy As a Switching Regimen in HIVTR Cohort Yagci-Caglayik D 1, Gokengin D 2, Inan A 3, Ozkan-Ozdemir H 4, Inan D 5, Akbulut A 6, Korten V 1,
More informationResistance to Integrase Strand Transfer Inhibitors
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Resistance to Integrase Strand Transfer Inhibitors David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases
More informationScottish Medicines Consortium
Scottish Medicines Consortium darunavir 300mg tablets (Prezista ) No. (378/07) Tibotec (a division of Janssen-Cilag Ltd) 4 May 2007 The Scottish Medicines Consortium has completed its assessment of the
More informationMDR HIV and Total Therapeutic Failure. Douglas G. Fish, MD Albany Medical College Albany, New York Cali, Colombia March 30, 2007
MDR HIV and Total Therapeutic Failure Douglas G. Fish, MD Albany Medical College Albany, New York Cali, Colombia March 30, 2007 Objectives Case study Definitions Fitness Pathogenesis of resistant virus
More informationHIV/AIDS CID 2003:37 (1 July) 113
MAJOR ARTICLE HIV/AIDS Antiretroviral Drug Resistance Testing in Adults Infected with Human Immunodeficiency Virus Type 1: 2003 Recommendations of an International AIDS Society USA Panel Martin S. Hirsch,
More informationHydroxyurea with ddi or ddi/d4t: a novel approach to HIV therapy
National AIDS Treatment Advocacy Project Hydroxyurea with ddi or ddi/d4t: a novel approach to HIV therapy Results from several hydroxyurea (ddi+hydroxyurea) studies were reported at Vancouver (July `96)
More information43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) A Cutrell, J Hernandez, M Edwards, J Fleming, W Powell, T Scott
43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Poster H-2013 Clinical Risk Factors for Hypersensitivity Reactions to Abacavir: Retrospective Analysis of Over 8,000 Subjects
More informationAntiviral Therapy 5: 41-48
Antiviral Therapy 5: 41-48 The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis
More informationHIV replication and selection of resistance: basic principles
HIV replication and selection of resistance: basic principles 26th International HIV Drug Resistance and Treatment Strategies Workshop Douglas Richman 6 November 2017 CLINICAL DATA DURING SIXTEEN WEEKS
More informationGuidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
More informationCONCISE COMMUNICATION
1688 CONCISE COMMUNICATION Vertical Transmission of Multidrug-Resistant Human Immunodeficiency Virus Type 1 (HIV-1) and Continued Evolution of Drug Resistance in an HIV-1 Infected Infant Victoria A. Johnson,
More informationNobel /03/28. HIV virus and infected CD4+ T cells
Mechanism of HIV drug resistance. Rodrigo Brindeiro / Amilcar Tanuri Laboratório de Virologia Molecular UFRJ 2 -Asso ciate Research Scientist, Internatio nal Center fo r Aids Care and Treatment Programs-ICAP,
More informationTreatment-Emergent Mutations and Resistance in HIV-Infected Children Treated with Fosamprenavir-Containing Antiretroviral Regimens
Send Orders for Reprints to reprints@benthamscience.ae 38 The Open AIDS Journal, 2015, 9, 38-44 Open Access Treatment-Emergent Mutations and Resistance in HIV-Infected Children Treated with Fosamprenavir-Containing
More informationDespite the wealth of efficacy data from
OPTIMIZING HIV DRUG THERAPY * John G. Bartlett, MD ABSTRACT The clinical success of highly active antiretroviral therapy (HAART) in the treatment of human immunodeficiency virus disease is one of the great
More informationMilan, Italy. Received 15 March 2002; returned 22 July 2002; revised 12 September 2002; accepted 27 September 2002
Journal of Antimicrobial Chemotherapy (2003) 51, 135 139 DOI: 10.1093/jac/dkg016 Comparison of levels of HIV-1 resistance to protease inhibitors by recombinant versus conventional virus phenotypic assay
More informationSelected Issues in HIV Clinical Trials
Selected Issues in HIV Clinical Trials Judith S. Currier, M.D., MSc Professor of Medicine Division of Infectious Diseases University of California, Los Angeles Issues Evolving Global and Domestic Epidemic
More informationDIVISION OF ANTIVIRAL DRUG PRODUCTS (HFD-530) MICROBIOLOGY REVIEW NDA:
Atazanavir (BMS-232632, ATV) Molecular Formula: C 38 H 52 N 6 O 7 H 2 SO 4 Molecular Weight: 704.9 Dosage Form(s): 100/150/200 mg capsule Route(s) of Administration: Oral Pharmacological Category: Indication(s):
More informationThis graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts
1 2 This graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts decreased. This period of acute infection or serocnversion
More informationTerapia antirretroviral inicial y de rescate: Utilidad actual y futura de nuevos medicamentos
Terapia antirretroviral inicial y de rescate: Utilidad actual y futura de nuevos medicamentos (Antiretroviral Therapy Present and Future Prospects of Antiretroviral Drugs in Initial and Salvage Therapy)
More informationThe rise and fall of triple nucleoside reverse transcriptase inhibitor (NRTI) regimens
Journal of Antimicrobial Chemotherapy (2004) 54, 587 592 DOI: 10.1093/jac/dkh384 Advance Access publication 28 July 2004 The rise and fall of triple nucleoside reverse transcriptase inhibitor (NRTI) regimens
More informationSelected Issues in HIV Clinical Trials
Selected Issues in HIV Clinical Trials Judith S. Currier, M.D., MSc Professor of Medicine Division of Infectious Diseases University of California, Los Angeles Issues Evolving Global and Domestic Epidemic
More informationClinical Management of HIV Drug Resistance
Viruses 2011, 3, 347-378; doi:10.3390/v3040347 OPEN ACCESS viruses ISSN 1999-4915 www.mdpi.com/journal/viruses Review Clinical Management of HIV Drug Resistance Karoll J. Cortez and Frank Maldarelli *
More informationHIV associated CNS disease in the era of HAART
HIV associated CNS disease in the era of HAART CSF/CNS penetration and efficacy Acknowledgements Peter Portegies Department of Neurology, AMC Mark van der Valk Department of Internal Medicine/Infectious
More informationKimberly Adkison, 1 Lesley Kahl, 1 Elizabeth Blair, 1 Kostas Angelis, 2 Herta Crauwels, 3 Maria Nascimento, 1 Michael Aboud 1
Pharmacokinetics of Dolutegravir and Rilpivirine After Switching to the Two-Drug Regimen From an Efavirenz- or Nevirapine- Based Antiretroviral Regimen: SWORD-1 & -2 Pooled PK Analysis Kimberly Adkison,
More informationHIV THERAPY STRATEGIES FOR THIRD LINE. issues to consider when faced with few drug options
STRATEGIES FOR THIRD LINE HIV THERAPY issues to consider when faced with few drug options A PUBLICATION FROM Information, Inspiration and Advocacy for People Living With HIV/AIDS MAY 2008 Most people living
More informationPaediatric Infectious Diseases Unit, Red Cross War Memorial Children s Hospital & University of Cape Town
A Public Sector Antiretroviral Treatment Programme for Treatment-Experienced Children and Adolescents in the Western Cape Province of South Africa Using Darunavir/Ritonavir-, Raltegravir- and Etravirine-Containing
More informationSpecial Contribution Questions to and Answers from the International AIDS Society USA Resistance Testing Guidelines Panel
Special Contribution Questions to and Answers from the International AIDS Society USA Resistance Testing Guidelines Panel In 1996 the International AIDS Society USA convened an international panel of experts
More informationDistribution and Effectiveness of Antiretrovirals in the Central Nervous System
Distribution and Effectiveness of Antiretrovirals in the Central Nervous System Scott Letendre, MD Associate Professor of Medicine HIV Neurobehavioral Research Center and Antiviral Research Center University
More informationSwitching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches
Switching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches Harry W. Lampiris, MD Chief, Infectious Disease Section, San Francisco VA Medical Center Professor
More informationDr Carole Wallis, PhD Medical Director, BARC-SA Head of the Specialty Molecular Division, Lancet Laboratories, South Africa
Dr Carole Wallis, PhD Medical Director, BARC-SA Head of the Specialty Molecular Division, Lancet Laboratories, South Africa Transmitted drug resistance Resistance patterns in first-line failures in adults
More informationThe advent of protease inhibitors (PIs) as PROCEEDINGS CLINICAL EXPECTATIONS OF EFFICACY: PROTEASE INHIBITOR POTENCY * Benjamin Young, MD, PhD
CLINICAL EXPECTATIONS OF EFFICACY: PROTEASE INHIBITOR POTENCY * Benjamin Young, MD, PhD ABSTRACT Tremendous strides were made in reducing the morbidity and mortality associated with HIV infection with
More informationAntiviral Therapy 14:
Antiviral Therapy 14:273 283 Original article Advantages of predicted phenotypes and statistical learning models in inferring virological response to antiretroviral therapy from HIV genotype André Altmann
More informationThe prevalence of antiretroviral drug resistance in the United States
The prevalence of antiretroviral drug resistance in the United States Douglas D. Richman a,b, Sally C. Morton c, Terri Wrin d, Nicholas Hellmann d, Sandra Berry c, Martin F. Shapiro c,e and Samuel A. Bozzette
More informationOccupational and Non- Occupational HIV Post-exposure Prophylaxis
Occupational and Non- Occupational HIV Post-exposure Prophylaxis Amy V. Kindrick, MD, MPH National Clinicians Post-Exposure Prophylaxis Hotline (PEPline) University of California, San Francisco San Francisco
More informationViral Resistance with Topical RT-Microbicides. Ian McGowan MD PhD FRCP David Geffen School of Medicine Los Angeles
Viral Resistance with Topical RT-Microbicides Ian McGowan MD PhD FRCP David Geffen School of Medicine Los Angeles verview What antiretrovirals (ARV) are being considered as candidate microbicides? How
More informationThe US Food and Drug Administration has
NEW ANTIRETROVIRAL AGENTS FOR TREATMENT-EXPERIENCED PATIENTS * Roy M. Gulick, MD, MPH ABSTRACT Antiretroviral treatment regimens currently available for the treatment of the human immunodeficiency virus
More informationAntiretroviral Therapy
Antiretroviral Therapy Scott M. Hammer, M.D. 1986 1990 ZDV monorx 1990 1995 Alternative NRTI monorx Combination NRTI Rx Introduction of NNRTI s Antiretroviral resistance Pathogenetic concepts Evolution
More informationHIV in the Brain MANAGING COMORBIDITIES IN PATIENTS WITH HIV
HIV in the Brain MANAGING COMORBIDITIES IN PATIENTS WITH HIV Shibani S. Mukerji MD, PhD Massachusetts General Hospital, Division of Immunologic, Inflammatory and Infectious Neurological Diseases Dana-Farber
More informationHIV-1 Protease and Reverse Transcriptase Mutation Patterns Responsible for Discordances Between Genotypic Drug Resistance Interpretation Algorithms
JAIDS Journal of Acquired Immune Deficiency Syndromes 33:8 14 2003 Lippincott Williams & Wilkins, Inc., Philadelphia Rapid Communication HIV-1 Protease and Reverse Transcriptase Mutation Patterns Responsible
More informationFirst line ART Rilpirivine A New NNRTI. Chris Jack Physician, Durdoc Centre ethekwini
First line ART Rilpirivine A New NNRTI Chris Jack Physician, Durdoc Centre ethekwini Overview: Rilpirivine an option for ARV Naïve patients History Current guidelines Efficacy and Safety Tolerability /
More informationSimplifying HIV Treatment Now and in the Future
Simplifying HIV Treatment Now and in the Future David M. Hachey, Pharm.D., AAHIVP Professor Idaho State University Department of Family Medicine Nothing Disclosure 1 Objectives List current first line
More informationPediatric HIV Update NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Pediatric HIV Update Christian B. Ramers, MD, MPH Assistant Medical Director, Family Health Centers of San Diego HIV/HCV Distance Education Specialist - NWAETC,
More informationCrafting an ART Regimen for Initiation or Salvage: Are NRTI s Necessary?
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Crafting an ART Regimen for Initiation or Salvage: Are NRTI s Necessary? Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical
More informationEvaluation and Management of Virologic Failure
National HIV Curriculum PDF created November 3, 2018, 12:26 am Evaluation and Management of Virologic Failure This is a PDF version of the following document: Section 1: Antiretroviral Therapy Topic 5:
More informationChallenges for the clinical development of new nucleoside reverse transcriptase inhibitors for HIV infection
Review Antiviral Therapy 10:13 28 Challenges for the clinical development of new nucleoside reverse transcriptase inhibitors for HIV infection Mark A Wainberg 1 *, James PC Sawyer 2, Julio SG Montaner
More informationSupplementary information
Supplementary information Dose-response Curve Slope Sets Class-Specific Limits on Inhibitory Potential of Anti-HIV Drugs Lin Shen 1,2, Susan Peterson 1, Ahmad R. Sedaghat 1, Moira A. McMahon 1,2, Marc
More informationVIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects
VIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects IL/DLG/0040/14 June 2014 GSK (Israel) Ltd. Basel 25, Petach Tikva. Tel-03-9297100 Medical information service: il.medinfo@gsk.com
More informationAntiretroviral Treatment Strategies: Clinical Case Presentation
Antiretroviral Treatment Strategies: Clinical Case Presentation Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan Chia-Jui, Yang M.D Disclosure No conflicts of interests.
More informationCLAUDINE HENNESSEY & THEUNIS HURTER
HIV/AIDS/TB CLAUDINE HENNESSEY & THEUNIS HURTER KEY TERMS Do these sound familiar? What strange terms do you hear in the clinics? Any others to add?? HIV AIDS Viral Load & suppression CD4 count Regimen
More informationLa terapia dell infezione da HIV: passato, presente e futuro.
1 st Infectivology Today Paestum (SA) 14-15 maggio 2004 La terapia dell infezione da HIV: passato, presente e futuro. Prof. Adriano Lazzarin Università Vita-Salute San Raffaele, Milano Scuola di Specializzazione
More informationOptimizing 2 nd and 3 rd Line Antiretroviral Therapy in Children and Adolescents
Optimizing 2 nd and 3 rd Line Antiretroviral Therapy in Children and Adolescents Victor Musiime, MBChB, MMED, PhD Senior Lecturer, Makerere University Investigator, Joint Clinical Research Centre (JCRC)
More information